Evaluation of symmetric dimethylarginine and creatinine in dogs with primary hypoadrenocorticism receiving long-term mineralocorticoid replacement therapy
| Autor: | Federico Fracassi, Nadja S Sieber-Ruckstuhl, Jose I. Casado Diaz, Felicitas S Boretti, Claudia E Reusch |
|---|---|
| Přispěvatelé: | University of Zurich, Casado Díaz, Jose I, Casado Diaz J.I., Sieber-Ruckstuhl N.S., Boretti F.S., Fracassi F., Reusch C.E. |
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: |
medicine.medical_specialty
10253 Department of Small Animals 040301 veterinary sciences Symmetric dimethylarginine medicine.drug_class 3400 General Veterinary Population Urology Renal function Arginine 0403 veterinary science chemistry.chemical_compound Dogs Addison Disease Mineralocorticoids Dog Desoxycorticosterone pivalate medicine Animals Dog Diseases education Creatinine education.field_of_study General Veterinary 630 Agriculture Animal business.industry 0402 animal and dairy science 04 agricultural and veterinary sciences General Medicine medicine.disease Serum samples 040201 dairy & animal science Mineralocorticoid chemistry 570 Life sciences biology business Kidney disease |
| DOI: | 10.5167/uzh-204530 |
| Popis: | Objectives To investigate kidney function by determining serum symmetric dimethylarginine (sSDMA) and serum creatinine (sCr) concentrations in dogs with primary hypoadrenocorticism (PH) receiving long-term mineralocorticoid replacement therapy. Methods Dogs with PH receiving a minimum of 12 months of either desoxycorticosterone pivalate or fludrocortisone acetate were included in the study provided that banked frozen serum samples were available for sSDMA analysis. sCr concentrations were retrieved from the medical records. In dogs still alive and presented for regular re-evaluations and in newly diagnosed patients, blood was prospectively collected for sSDMA and sCr determination. Results Thirty-two dogs met the inclusion criteria. The treatment time ranged from 12 to 146 months after initial diagnosis (median, 55.5 months). The majority of dogs had normal sSDMA and sCr concentrations throughout the hormone replacement treatment. Both sSDMA and sCr concentrations were persistently elevated in three of 32 dogs. Further workup confirmed chronic kidney disease (CKD) in all three dogs. Conclusions Based on these data, the prevalence of CKD could be higher in dogs with PH receiving long-term mineralocorticoid replacement treatment than in the general dog population. However, additional studies with a larger number of dogs are needed to confirm it. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|